Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Cooper

Showing results (131-140 of 201) with videos related to

Pageof 21
Sort By:
International Journal of Oncology|July 13, 2005
Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agentsSoo Lo, Berend Tolner, Jan-Willem Taanman, et al.
Annals of Neurology|October 5, 2012
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsMatthew E Gegg, Derek Burke, Simon J R Heales, et al.
Diabetes Care|March 21, 2020
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A<sub>1c</sub> in the ADVANCE TrialJingyan Tian, Toshiaki Ohkuma, Mark Cooper, et al.
Journal of Experimental Botany|May 31, 2022
Radiation use efficiency increased over a century of maize (Zea mays L.) breeding in the US corn beltCarlos D Messina, Jose Rotundo, Graeme L Hammer, et al.
Archives of Neurology|August 11, 2010
Chaperone-mediated autophagy markers in Parkinson disease brainsLydia Alvarez-Erviti, Maria C Rodriguez-Oroz, J Mark Cooper, et al.
Neurology|February 22, 2013
A novel α-synuclein missense mutation in Parkinson diseaseChristos Proukakis, Christopher G Dudzik, Timothy Brier, et al.
Diabetes Care|May 10, 2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trialYoichiro Hirakawa, Hisatomi Arima, Sophia Zoungas, et al.
Cardiovascular Diabetology|July 29, 2017
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetesKamel Mohammedi, Mark Woodward, Michel Marre, et al.
Heart, Lung & Circulation|October 12, 2016
Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved OutcomesKaram Kostner, Stephen Nicholls, John Amerena, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 24, 2003
Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular diseaseJin H Li, Xiao R Huang, Hong-Jian Zhu, et al.
Pageof 21

Showing results (131-140 of 201) with videos related to

Sort By:
Pageof 21
International Journal of Oncology|July 13, 2005
Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agentsSoo Lo, Berend Tolner, Jan-Willem Taanman, et al.
Annals of Neurology|October 5, 2012
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsMatthew E Gegg, Derek Burke, Simon J R Heales, et al.
Diabetes Care|March 21, 2020
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A<sub>1c</sub> in the ADVANCE TrialJingyan Tian, Toshiaki Ohkuma, Mark Cooper, et al.
Journal of Experimental Botany|May 31, 2022
Radiation use efficiency increased over a century of maize (Zea mays L.) breeding in the US corn beltCarlos D Messina, Jose Rotundo, Graeme L Hammer, et al.
Archives of Neurology|August 11, 2010
Chaperone-mediated autophagy markers in Parkinson disease brainsLydia Alvarez-Erviti, Maria C Rodriguez-Oroz, J Mark Cooper, et al.
Neurology|February 22, 2013
A novel α-synuclein missense mutation in Parkinson diseaseChristos Proukakis, Christopher G Dudzik, Timothy Brier, et al.
Diabetes Care|May 10, 2014
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trialYoichiro Hirakawa, Hisatomi Arima, Sophia Zoungas, et al.
Cardiovascular Diabetology|July 29, 2017
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetesKamel Mohammedi, Mark Woodward, Michel Marre, et al.
Heart, Lung & Circulation|October 12, 2016
Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved OutcomesKaram Kostner, Stephen Nicholls, John Amerena, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 24, 2003
Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular diseaseJin H Li, Xiao R Huang, Hong-Jian Zhu, et al.
Pageof 21